Lipoprotein alterations and reduced growth hormone secretion: relationships with obesity and cardiovascular risk.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches.Nutrients · 2013
   Review
2. The role of psychobiological and neuroendocrine mechanisms in appetite regulation and obesity.The open cardiovascular medicine journal · 2012
   Article

Corrections and comments

• Comment on
  Reduced growth hormone secretion in obesity is associated with smaller LDL and HDL particle size.2012

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as